Literature DB >> 27742851

The role of calculated non-caeruloplasmin-bound copper in Wilson's disease.

Andrew Duncan1, Calum Yacoubian1, Robert Beetham2, Anthony Catchpole1, David Bullock3.   

Abstract

Background US and European guidelines suggest the use of calculated non-caeruloplasmin-bound copper (free copper index) for the diagnosis and management of Wilson's Disease. However, there is concern that the required analytical measurements of caeruloplasmin and copper may not be sufficiently robust at the concentrations usually found. Methods Aliquots of six plasma specimens were sent to laboratories participating in the UK National External Quality Assessment Scheme for copper and caeruloplasmin. The variability of these two reported measurements and the calculated non-caeruloplasmin-bound copper concentrations were compared. The variability of caeruloplasmin reference ranges quoted by laboratories was also investigated. Results No laboratories use the required enzymatic methods in the calculation of non-caeruloplasmin-bound copper. The interlaboratory variations in caeruloplasmin concentrations and calculated non-caeruloplasmin-bound copper concentrations were very considerable so making clinical interpretation unreliable. Wide differences in the caeruloplasmin reference ranges used were also found. Conclusions Such variations of the calculated non-caeruloplasmin-bound copper concentrations and the predominant use of immunological methods for measuring caeruloplasmin preclude a clinical role for this calculated value in the investigation of Wilson's disease.

Entities:  

Keywords:  Inborn errors of metabolism; clinical studies

Mesh:

Substances:

Year:  2016        PMID: 27742851     DOI: 10.1177/0004563216676843

Source DB:  PubMed          Journal:  Ann Clin Biochem        ISSN: 0004-5632            Impact factor:   2.057


  5 in total

Review 1.  Update on the Diagnosis and Management of Wilson Disease.

Authors:  Eve A Roberts
Journal:  Curr Gastroenterol Rep       Date:  2018-11-05

Review 2.  Practical insights into chronic management of hepatic Wilson's disease.

Authors:  Erica Nicola Lynch; Claudia Campani; Tommaso Innocenti; Gabriele Dragoni; Paolo Forte; Andrea Galli
Journal:  World J Clin Cases       Date:  2022-05-16       Impact factor: 1.534

3.  Biomarkers for diagnosis of Wilson's disease.

Authors:  Aidan Ryan; Sarah J Nevitt; Orla Tuohy; Paul Cook
Journal:  Cochrane Database Syst Rev       Date:  2019-11-19

4.  Characteristics of a newly diagnosed Polish cohort of patients with neurological manifestations of Wilson disease evaluated with the Unified Wilson's Disease Rating Scale.

Authors:  Anna Członkowska; Tomasz Litwin; Karolina Dzieżyc; Michal Karliński; Johan Bring; Carl Bjartmar
Journal:  BMC Neurol       Date:  2018-04-05       Impact factor: 2.474

Review 5.  Chelation therapy in liver diseases of childhood: Current status and response.

Authors:  Jayendra Seetharaman; Moinak Sen Sarma
Journal:  World J Hepatol       Date:  2021-11-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.